Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Free Cash Flow (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Free Cash Flow for 3 consecutive years, with -$37.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 18.79% to -$37.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$181.4 million, a 39.12% decrease, with the full-year FY2025 number at -$181.4 million, down 39.12% from a year prior.
  • Free Cash Flow was -$37.5 million for Q4 2025 at Nuvation Bio, up from -$52.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$15.0 million in Q4 2023 to a low of -$52.9 million in Q3 2025.
  • A 3-year average of -$31.7 million and a median of -$34.3 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 206.65% in 2024, then rose 18.79% in 2025.
  • Nuvation Bio's Free Cash Flow stood at -$15.0 million in 2023, then plummeted by 206.65% to -$46.1 million in 2024, then increased by 18.79% to -$37.5 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Free Cash Flow are -$37.5 million (Q4 2025), -$52.9 million (Q3 2025), and -$48.4 million (Q2 2025).